Genetic polymorphisms to identify patients with an optimal response to tildrakizumab in psoriasis patients from real-life clinical practice

Detecting the association of genetic variants to the response of biological therapy represents an important advance in developing a personalized therapy. The aim of this work was to study the association of polymorphisms with an optimal response to tildrakizumab in patients with psoriasis in a real-...

Full description

Bibliographic Details
Authors: Butrón-Bris, B., Ovejero-Benito, M. C., Santos-Juanes, J., Martínez-López, A., Ruiz-Villaverde, R., Baniandrés, O., Izu-Belloso, R., de la Cueva, P., Sahuquillo-Torralba, A., Gónzalez-Quesada, A., Vilarrasa-Rull, E., Pujol-Montcusí, J., García-Martínez, J., Navares, M., Palomar-Moreno, I., Novalbos, J., Abad Santos, Francisco, Daudén Tello, Esteban, de la Fuente, H., Llamas Velasco, María del Mar, Roustan Gullón, Luis Gastón
Format: article
Publication Date:2024
Country:España
Institution:Universidad Autónoma de Madrid
Repository:Biblos-e Archivo. Repositorio Institucional de la UAM
Language:English
OAI Identifier:oai:repositorio.uam.es:10486/720574
Online Access:http://hdl.handle.net/10486/720574
https://dx.doi.org/10.1111/exd.15152
Access Level:Open access
Keyword:effectiveness
genetic variants
psoriasis
tildrakizumab
Medicina
Description
Summary:Detecting the association of genetic variants to the response of biological therapy represents an important advance in developing a personalized therapy. The aim of this work was to study the association of polymorphisms with an optimal response to tildrakizumab in patients with psoriasis in a real-life clinical practice. Ninety patients with plaque psoriasis recruited from—Spanish hospitals receiving tildrakizumab for at least 24 weeks were genotyped for 180 polymorphisms. Optimal response to tildrakizumab was evaluated by absolute PASI ≤1 at 6 and 12 months. Polymorphisms corrected for weight and disease duration with an FDR <0.15 were included in a multiple regression model. Sixty three percent of patients achieved an absolute PASI ≤1 at 6 months, while 71% did so after 12 months. Disease duration (>27 years) and weight (>76 kg) were associated with treatment response; after correcting by these factors, no association (FDR >0.15) was found for any polymorphism and response to tildrakizumab at 6 months. The analysis at 12 months identified the genotype GG for rs610604 (TNFAIP3), CT for rs9373839 (ATG5), and delCTGT/delCTGT for rs72167053 (PDE4D) as risk factors to not achieve an optimal response (PASI ≤1), while CT for rs708567 (IL17RC) was protective, independently of weight and disease duration (FDR <0.15). The final multivariable model at 12 months showed an AUC of 0.90 (95% CI 0.82 to −0.98). We identified a set of polymorphisms that could be helpful to identify psoriatic patients with an optimal response to tildrakizumab at 12 months in real-world practice conditions

Similar Items